Evidence map›Paper›PMID 35354949›Full record

ArticleCancer gene therapy2022

Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting.

Yichu Nie, Fenglan Feng, Wei Luo, Andrew J Sanders, Yidi Zhang, Jiaming Liang, Cheng Chen, Weineng Feng, Weiquan Gu, Weiping Liao and 5 more

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Cancer gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Molecular mechanisms and therapeutic targets in lung cancer-nerve crosstalk.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Phenolic Compounds and Capsaicinoids in ThreeMolecules (Basel, Switzerland) · 2023
    Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Yichu Nie *Clinical Research Institute, The First People's Hospital of Foshan & Sun Yat-sen University Foshan Hospital, Foshan, 528000, PR China.
Fenglan Feng *State Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, 510120, PR China.
Wei Luo *Clinical Research Institute, The First People's Hospital of Foshan & Sun Yat-sen University Foshan Hospital, Foshan, 528000, PR China.
Andrew J SandersCCMRC, Cardiff University School of Medicine, Cardiff, UK.
Yidi ZhangSchool of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Guangzhou, 510275, PR China.
Jiaming LiangState Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, 510120, PR China.
Cheng ChenState Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, 510120, PR China.
Weineng FengClinical Research Institute, The First People's Hospital of Foshan & Sun Yat-sen University Foshan Hospital, Foshan, 528000, PR China.
Weiquan GuClinical Research Institute, The First People's Hospital of Foshan & Sun Yat-sen University Foshan Hospital, Foshan, 528000, PR China.
Weiping LiaoFoshan Fourth People's Hospital, Foshan, 528000, PR China.
Wei WangFoshan Fourth People's Hospital, Foshan, 528000, PR China.
Jinfeng ChenPeking University Cancer Hospital and Beijing Cancer Institute, Department of Thoracic Surgery, Fucheng Road, Haidian District, Beijing, China.
Lijian ZhangPeking University Cancer Hospital and Beijing Cancer Institute, Department of Thoracic Surgery, Fucheng Road, Haidian District, Beijing, China.
Wen G JiangCCMRC, Cardiff University School of Medicine, Cardiff, UK.
Jin LiState Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, 510120, PR China. JinL@gzhmu.edu.cn.ORCID http://orcid.org/0000-0002-7182-7510
Sun Yat-sen University · CNFirst Affiliated Hospital of Guangzhou Medical University · CNCardiff University · GBPeking University · CNThe Fourth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The specific biological function of transient receptor potential vanilloid 1 (TRPV1) in pathogenesis of lung adenocarcinoma (LUAD) remains unclear. In this study, TRPV1 expression in tumor tissues, primary cells and cell lines of LUAD, as well as the mechanism mediating its hyperexpression were systematically studied. Multiple models and techniques were adopted to elucidate the relationship between TRPV1 hyperexpression and tumor recurrence and metastasis. Results showed that TRPV1 expression was increased in tumor tissues and primary tumor cells of LUAD patients. The increased expression was associated with worse overall survival outcome and raised HIF1α levels. TRPV1 expression in A549 and NCI-H292 cells was increased after pretreatment with cigarette smoke extract or spermine NONOate. Moreover, A549 cells with TRPV1 overexpression has enhanced tumor growth rates in subcutaneous grafted tumor models, and increased intrapulmonary metastasis after tail vein infusion in nude BALB/c nude mice. Mechanistically, TRPV1 overexpression in A549 cells promoted HIF1α expression and nuclear translocation by promoting CREB phosphorylation and activation of NOS1-NO pathway, ultimately leading to accelerated cell proliferation and stronger invasiveness. In addition, based on photothermal effects, CuS-TRPV1 mAb effectively targeted and induced apoptosis of TRPV1-A549 cells both in vivo and in vitro, thereby mitigating tumor growth and metastasis induced by xenotransplantation of TRPV1-A549 cells. In conclusion, TRPV1 hyperexpression in LUAD is a risk factor for tumor progression and is involved in proliferation and migration of tumor cells through activation of HIF1α. Our study also attempted a new strategy inhibiting the recurrence and metastasis of LUAD: by CuS-TRPV1 mAb precisely kill TRPV1 hyperexpression cells through photothermal effects.

Indexed as

Adenocarcinoma of LungLung NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationCopperGene Expression Regulation, NeoplasticMiceMice, Inbred BALB CMice, NudeTRPV Cation ChannelsCoppercupric sulfideTRPV1 protein, humanTRPV1 protein, mouseTRPV Cation Channels

Identifiers

PMID35354949
PMCPMC9576597
OpenAlexW4220934027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.